ES-SCLC: Trilaciclib for Chemo-Induced Myelosuppression
September 9th 2021
Jared Weiss, MD, of UNC Lineberger Comprehensive Cancer Center, highlights clinical trial data that led to the approval of trilaciclib in patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.